https://www.selleckchem.com/pr....oducts/Vandetanib.ht
67-0.89) and 0.73 (95% CI, 0.59-0.87) in the training and validation cohorts, respectively. Radiomics nomogram, incorporating the radiomics signature with the conventional clinical variables, also performed well in the two cohorts (training cohort AUC, 0.84; validation cohort AUC, 0.82). Moreover, we found that the high-risk patients determined by our radiomics nomogram could benefit from postoperative adjuvant chemotherapy, while the low-risk and total patient groups could not. Our novel radiomics nomogram is a promising and favorab
Like
Comment
Share
